Affiliations: Centre for Biomaterial Development, GKSS Research Centre, Teltow, Germany | Central Institute for Biomedical Engineering, Department for Biomaterials, University of Ulm, Ulm, Germany | BCRT, Charité, Campus Virchow, Berlin, Germany
Note: [] Corresponding author: Dr. B. Hiebl, Centre for Biomaterial Development, GKSS Research Centre, Kantstr. 55, 14513 Teltow, Germany. E-mail: bernhard.hiebl@gkss.de.
Abstract: Monocytes are broadly discussed in the literature as cells, which can get properties of endothelial progenitor cells after angiogenic stimulation. Angiogenically stimulated monocytes can be used to promote implant vascularisation. A necessity therefore is that these cells can be stored and used after storage without a loose of their characteristic phenotype. In this study we tested, if freshly thawed cryopreserved human monocytes are positive for the mo/macrophage markers CD14 and CD68 and the endothelial marker CD31 after thawing and following angiogenic stimulation in a VEGF-A165 enriched (10 ng/ml) angiogenic medium. Thereby the monocytes were tested before and after differentiation towards macrophages. The results revealed that freshly thawed human CD14 positive monocytes are positive for CD14, CD68 and CD31 after angiogenic stimulation. This CD specification was much more intense in the differentiated cells. The differentiation step also resulted in an increased cell count. Both results can be attributed to the method of differentiation, were cell culture bags were used instead of common cell culture dishes. Additionally the differentiation medium (X-VIVO 10+10% FCS) was specifically adapted to the requirements of monocytes/macrophages. The study showed that human CD14 positive monocytes can be thawed after cryopreservation without loss of their monocytes/macrophage phenotype and without loss of their ability to get angiogenically stimulated. To enhance the efficiency of both steps (thawing, angiogenic stimulation) it can be useful to differentiate the thawed cells in cell culture bags by the use of X-VIVO 10 (+10% FCS) before angiogenic stimulation.
